Anixa Biosciences (ANIX) - Gross Return on Sales

Official company branding of Anixa Biosciences (ANIX)

Anixa Biosciences is engaged in a patent battle within the high-risk vaccine race, leveraging streamlined component supply chains. On GURU.Markets, the gross margin reflects profit dynamics net of costs, with the indicator standing at 0.00. Proprietary developments in the treatment of female cancers create barriers to entry, transforming future products into high-yield assets.

anixa.com (ANIX) Return on Gross Profit: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for anixa.com (ANIX)

- current quotes and average value forecast:
- market capitalization indicators:
Basic company analysis:ANIX Anixa Biosciences
Finished products of Anixa Biosciences, Inc.

Automation of breast cancer drug synthesis at Anixa Biosciences (ANIX) reduces costs, yet medical oversight expenses in clinics directly impact the cost of goods sold. The gross margin as a percentage of revenue reflects the efficiency of this balance, measuring the percentage of funds remaining after covering direct production costs, which allows investors to assess the fundamental profitability of the business through historical peaks and troughs.